{"organizations": [], "uuid": "0852edbddc6a81e0c463302bcec6a0a24fce9708", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-pfizer-has-not-received-acceptable/brief-pfizer-has-not-received-acceptable-offer-for-consumer-health-idUSL1N1S80LS", "country": "US", "domain_rank": 408, "title": "BRIEF-Pfizer Has Not Received Acceptable Offer For Consumer Health", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T18:23:00.000+03:00", "replies_count": 0, "uuid": "0852edbddc6a81e0c463302bcec6a0a24fce9708"}, "author": "", "url": "https://www.reuters.com/article/brief-pfizer-has-not-received-acceptable/brief-pfizer-has-not-received-acceptable-offer-for-consumer-health-idUSL1N1S80LS", "ord_in_thread": 0, "title": "BRIEF-Pfizer Has Not Received Acceptable Offer For Consumer Health", "locations": [], "entities": {"persons": [{"name": "bill berkrot", "sentiment": "none"}], "locations": [], "organizations": [{"name": "pfizer", "sentiment": "none"}, {"name": "sumer health reuters staff", "sentiment": "none"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1, 2018 / 3:27 PM / Updated 4 minutes ago BRIEF-Pfizer Has Not Received Acceptable Offer For Consumer Health Reuters Staff 1 Min Read\nMay 1 (Reuters) - Pfizer Inc:\n* PFIZER CEO SAYS HAS NOT YET RECEIVED AN ACCEPTABLE OFFER FOR CONSUMER HEALTH BUSINESS, MAY DECIDE TO RETAIN IT\n* PFIZER CEO SAYS THROUGH 2022 HAS 15 POTENTIAL BLOCKBUSTER DRUGS IN DEVELOPMENTAL PIPELINE\n* PFIZER CEO SAYS DONâ€™T SEE NEED FOR TRANSFORMATIVE DEAL OR SEE ONE AT APPROPRIATE VALUE Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)", "external_links": [], "published": "2018-05-01T18:23:00.000+03:00", "crawled": "2018-05-01T18:42:14.007+03:00", "highlightTitle": ""}